New indication approved for Guerbet’s Lipiodol® Ultra Fluid 2018

Guerbet makes the CDP A- grade for its commitment to the fight against global warming

Revenue at September 30, 2020

National Medical Products Administration (NMPA) approves Lipiodol® Ultra-Fluid for trans-arterial chemoembolization for hepatocellular carcinoma (HCC) at intermediate-stage in adult patients in China

UK approves Lipiodol® Ultra Fluid for hysterosalpingography in women undergoing infertility workup

Czech Republic approves Lipiodol® Ultra Fluid for hysterosalpingography in women undergoing infertility workup

Guerbet commits to patients affected by infertility during the European Fertility Week

Guerbet appoints a second director representing employees to its board

Therapeutic Goods Administration (TGA) approves both an additional indication for Guerbet’s Lipiodol® Ultra-Fluid & Vectorio® in Australia